Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has achieved a major milestone in its Phase 2 SEISMiC C study, announcing the planned enrollment of 20 patients for its interim …
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment Read More